The use of nanoparticulates to treat breast cancer
Nanoparticle-based platforms for breast cancer offer improved targeting, prolonged circulation, and enhanced drug accumulation, overcoming limitations of conventional therapies.
Breast cancer is a multi-stage disease that unfolds with the utmost complexity and heterogeneity of various cell types; thus, the unraveling of its molecular mechanisms is required to develop improved therapeutic strategies. This review tries to dissect the complex landscape related to changes in gene expression control dynamics in breast cancer. The large area of gene mutations is discussed, pointing out their important part in the pathogenesis of the disease. The article further explains the heterogeneity of tumors, unwinding the hormone receptor pathways responsible for the variability in disease presentation. We also conducted a thorough examination of the tumor microenvironment, uncovering the complex involvement of immune cells in both protecting against and promoting tumor growth. This analysis uncovered tactics employed by tumors to evade the immune system. All in all, this review has strong implications for the understanding of molecular mechanisms and subsequently provides a background for current improvements in targeted therapy. The use of illustrative figures aids in enhancing the understanding of the complex molecular mechanisms underlying breast cancer.
Breast cancer remains a major health challenge, and current treatments often lack specificity and cause severe side effects. Nanotechnology has the potential to revolutionize breast cancer therapy by enabling precise drug delivery and minimizing toxicity, thereby improving patient outcomes.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC